Medicare GLP-1 bridge starts with $50 copay and tight eligibility rules

CMS has launched a temporary national Medicare demonstration that gives some eligible Part D beneficiaries access to certain GLP-1 weight-loss drugs for a $50 monthly copay. The bridge began July 1 and is scheduled to run through December 31, 2027, making it a short-term federal test of whether obesity-drug coverage can work within Medicare.

Who can qualify

Not every Medicare beneficiary is included. CMS says the bridge is limited to people with Part D coverage who meet its clinical and plan rules and who are using the drug for weight management, not for broad or automatic access to GLP-1 medications. Beneficiaries who already receive a GLP-1 through Part D for another covered use do not qualify for the bridge.

CMS says a provider must complete prior authorization and confirm that the patient meets the program’s age, body-mass-index and diagnosis requirements. The agency also says pharmacies, plans and clinicians are still working through implementation details, so the rollout is not a simple one-step switch for every patient.

Which drugs are included

CMS says the bridge covers a short list of GLP-1 products it names on the program page, including Wegovy and Zepbound in the forms CMS specifies. The program is not a blanket Medicare benefit for every GLP-1 drug or every use of those medicines.

The $50 copay is the central consumer-facing change, but it does not mean open-ended coverage. CMS is using a centralized prior-authorization and claims process, and the demonstration is temporary. The bigger question now is whether the data from this bridge helps shape a longer-term Medicare policy on obesity treatment.

Sources

• CMS: Medicare GLP-1 Bridge program page
• Medicare.gov: Weight-loss drugs coverage page